{
    "name": "cysteamine",
    "comment": "Rx",
    "other_names": [
        "Cystagon",
        "Procysbi"
    ],
    "classes": [
        "Metabolic & Endocrine",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/cystagon-cysteamine-procysbi-342843",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to inform any drug-associated risks for birth defects or miscarriage; use during pregnancy only if potential benefits justify potential risk to fetus",
            "Cysteamine (administered as cysteamine bitartrate) was teratogenic and fetotoxic in rats at doses less than the recommended human maintenance dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information on the presence of cysteamine in human milk, the effects on the breast-fed infant, or the effects on milk production",
            "Cysteamine is present in the milk of lactating rats ",
            "Owing to the potential for serious adverse reactions in breastfed infants from cysteamine, breastfeeding is not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to cysteamine or penicillamine"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Skin and bone lesions that resemble clinical findings for Ehlers-Danlos-like syndrome reported in patients treated with high doses of immediate-release cysteamine bitartrate or other cysteamine salts; these include molluscoid pseudotumors (purplish hemorrhagic lesions), skin striae, bone lesions (including osteopenia, compression fractures, scoliosis and genu valgum), leg pain, and joint hyperextension; monitor for development of skin or bone lesions and interrupt dosing if patients develop these lesions; restart at a lower dose under close supervision, then slowly increase to the appropriate therapeutic dose",
                "Severe skin rashes (eg, erythema multiforme bullosa, toxic epidermal necrolysis) reported; if severe skin rashes develop, permanently discontinue use ",
                "Gastrointestinal (GI) ulceration and bleeding have been reported; GI tract symptoms including nausea, vomiting, anorexia and abdominal pain, sometimes severe; if severe GI tract symptoms develop, consider decreasing the Procysbi dose",
                "May cause CNS symptoms such as seizures, lethargy, somnolence, depression, and encephalopathy; interrupt medication or adjust the dose as necessary for patients with severe symptoms or with symptoms that persist or progress; may impair their ability to perform tasks such as driving or operating machinery",
                "Cysteamine has been associated with reversible leukopenia and elevated alkaline phosphatase levels",
                "Benign intracranial hypertension (pseudotumor cerebri; PTC) and/or papilledema have been reported; monitor for signs and symptoms of PTC, including headache, tinnitus, dizziness, nausea, diplopia, blurry vision, loss of vision, pain behind the eye or pain with eye movement; if signs/symptoms persist, interrupt or decrease dose and refer to an ophthalmologist; if diagnosis is confirmed, permanently discontinue use"
            ],
            "specific": [
                {
                    "type": "Fibrosing colonopathy",
                    "description": [
                        "Fibrosing colonopathy, including colonic stricture formation, reported in pediatric and young adult patients with nephropathic cystinosis; some of the patients had been treated for prolonged periods of time",
                        "Reported symptoms include abdominal pain, vomiting, bloody or persistent diarrhea, and fecal incontinence; evaluate patients with severe, persistent, and/or worsening abdominal symptoms for fibrosing colonopathy; if diagnosis is confirmed, permanently discontinue therapy and switch to immediate-release cysteamine bitartrate capsules",
                        "An association between methacrylic acid-ethyl acrylate copolymer (an inactive ingredient of this drug) and fibrosing colonopathy cannot be ruled out"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Drugs that increase the gastric pH (eg, medications containing bicarbonate or carbonate) may alter the pharmacokinetics of cysteamine due to the premature release of cysteamine and increase WBC cystine concentration; monitor WBC cystine concentration when drugs that increase the gastric pH are concomitantly used",
                        "Consumption of alcohol with cysteamine may increase the rate of cysteamine release and/or adversely alter the pharmacokinetic properties, as well as the effectiveness and toxicities; therefore, do not consume alcoholic beverages during treatment"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Vomiting",
            "percent": "12"
        },
        {
            "name": "emesis",
            "percent": "19-77"
        },
        {
            "name": "Vomiting",
            "percent": "53"
        },
        {
            "name": "emesis",
            "percent": "24"
        },
        {
            "name": "Gastroenteritis",
            "percent": "16-18"
        },
        {
            "name": "viral gastroenteritis",
            "percent": "14"
        },
        {
            "name": "Breath odor",
            "percent": "12"
        },
        {
            "name": "Nausea",
            "percent": "9-12"
        },
        {
            "name": "Abdominal pain",
            "percent": "7"
        },
        {
            "name": "discomfort",
            "percent": "5"
        },
        {
            "name": "Electrolyte imbalance",
            "percent": "5"
        },
        {
            "name": "Headache",
            "percent": "2"
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "loss of appetite",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "loss of appetite",
            "percent": null
        }
    ]
}